Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | FPR2 | P25090 | 12/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4893582 | 0.83 | ALPL (0.51) | SMN1; SMN2FPR2KDM4EALDH1A1 | |
| SCHEMBL4892376 | 0.81 | ALPG (0.53) | FPR2KDM4EALDH1A1TSHR | |
| SCHEMBL4888558 | 0.80 | ALPG (0.43) | FPR2KDM4EALDH1A1KCNH2 | |
| SCHEMBL4891109 | 0.78 | KDM4E (0.40) | FPR2KDM4EALDH1A1TSHR | |
| SCHEMBL27680813 | 0.75 | SMN1; SMN2 (0.44) | SMN1; SMN2FPR2CYP2D6TSHRCYP2C19 | |
| SCHEMBL2627812 | 0.73 | SMN1; SMN2 (0.69) | SMN1; SMN2FPR2CYP2D6TSHRCYP2C19 | |
| SCHEMBL20372281 | 0.71 | ALDH1A1 (0.55) | SMN1; SMN2KDM4EALDH1A1TSHR | |
| SCHEMBL4893983 | 0.71 | KDM4E (0.44) | KDM4EALDH1A1TSHRCYP2C19 | |
| SCHEMBL4554609 | 0.70 | CYP19A1 (0.50) | KDM4EALDH1A1 | |
| SCHEMBL4774262 | 0.70 | ALDH1A1 (0.53) | SMN1; SMN2KDM4EALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021012-A1 | 3-[4-{6-Substituted Alkanoyl Pyridin-3-Yl}-3-Phenyl]-5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones As Antibacterial Agents | ASTRAZENECA AB (SE) | 2008-01-24 | — | — | US | disclosed |
| US-20080021012-A1 | 3-[4-{6-Substituted Alkanoyl Pyridin-3-Yl}-3-Phenyl]-5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones As Antibacterial Agents | ASTRAZENECA AB (SE) | 2008-01-24 | — | — | US | disclosed |
| US-20080021012-A1 | 3-[4-{6-Substituted Alkanoyl Pyridin-3-Yl}-3-Phenyl]-5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones As Antibacterial Agents | ASTRAZENECA AB (SE) | 2008-01-24 | — | — | US | disclosed |
| EP-1753754-A1 | 3- '4- {6-SUBSTITUTED ALKANOYL) PYRIDIN-3-YL} -3-PHENYL! -5- (1H-1, 2, 3-TRIAZOL-1-YLMETHYL) -1, 3-OXAZOLIDIN-2-ONES AS ANTIBACTERIAL AGENTS | AstraZeneca AB (SE) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005116022-A1 | 3- `4- {6-SUBSTITUTED ALKANOYL) PYRIDIN-3-YL} -3-PHENYL! -5- (1H-1, 2, 3-TRIAZOL-1-YLMETHYL) -1, 3-OXAZOLIDIN-2-ONES AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021012-A1 | 3-[4-{6-Substituted Alkanoyl Pyridin-3-Yl}-3-Phenyl]-5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones As Antibacterial Agents | MRPL21, ARG1, OXA1L | SMN1; SMN2 2633/4885FPR2 590/4885KDM4E 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.